BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 22184053)

  • 1. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.
    Sun JD; Liu Q; Wang J; Ahluwalia D; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP
    Clin Cancer Res; 2012 Feb; 18(3):758-70. PubMed ID: 22184053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
    Li S; Zhang J; Li J; Chen D; Matteucci M; Curd J; Duan JX
    Biol Trace Elem Res; 2010 Sep; 136(3):294-301. PubMed ID: 19838642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation-An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302.
    Saggar JK; Tannock IF
    Clin Cancer Res; 2015 May; 21(9):2107-14. PubMed ID: 25677696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies.
    Takakusagi Y; Kishimoto S; Naz S; Matsumoto S; Saito K; Hart CP; Mitchell JB; Krishna MC
    Antioxid Redox Signal; 2018 Jan; 28(2):131-140. PubMed ID: 28741367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging.
    Peeters SG; Zegers CM; Biemans R; Lieuwes NG; van Stiphout RG; Yaromina A; Sun JD; Hart CP; Windhorst AD; van Elmpt W; Dubois LJ; Lambin P
    Clin Cancer Res; 2015 Jul; 21(13):2984-92. PubMed ID: 25805800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
    Benito J; Ramirez MS; Millward NZ; Velez J; Harutyunyan KG; Lu H; Shi YX; Matre P; Jacamo R; Ma H; Konoplev S; McQueen T; Volgin A; Protopopova M; Mu H; Lee J; Bhattacharya PK; Marszalek JR; Davis RE; Bankson JA; Cortes JE; Hart CP; Andreeff M; Konopleva M
    Clin Cancer Res; 2016 Apr; 22(7):1687-98. PubMed ID: 26603259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.
    Takakusagi Y; Matsumoto S; Saito K; Matsuo M; Kishimoto S; Wojtkowiak JW; DeGraff W; Kesarwala AH; Choudhuri R; Devasahayam N; Subramanian S; Munasinghe JP; Gillies RJ; Mitchell JB; Hart CP; Krishna MC
    PLoS One; 2014; 9(9):e107995. PubMed ID: 25254649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.
    Portwood S; Lal D; Hsu YC; Vargas R; Johnson MK; Wetzler M; Hart CP; Wang ES
    Clin Cancer Res; 2013 Dec; 19(23):6506-19. PubMed ID: 24088735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
    Meng F; Bhupathi D; Sun JD; Liu Q; Ahluwalia D; Wang Y; Matteucci MD; Hart CP
    BMC Cancer; 2015 May; 15():422. PubMed ID: 25994202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.
    Liapis V; Zinonos I; Labrinidis A; Hay S; Ponomarev V; Panagopoulos V; Zysk A; DeNichilo M; Ingman W; Atkins GJ; Findlay DM; Zannettino AC; Evdokiou A
    Cancer Med; 2016 Mar; 5(3):534-45. PubMed ID: 26749324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.
    Sun JD; Liu Q; Ahluwalia D; Ferraro DJ; Wang Y; Jung D; Matteucci MD; Hart CP
    Cancer Biol Ther; 2016 Apr; 17(4):371-80. PubMed ID: 26818215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer.
    Sun JD; Liu Q; Ahluwalia D; Li W; Meng F; Wang Y; Bhupathi D; Ruprell AS; Hart CP
    Cancer Biol Ther; 2015; 16(3):438-49. PubMed ID: 25679067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.
    Meng F; Evans JW; Bhupathi D; Banica M; Lan L; Lorente G; Duan JX; Cai X; Mowday AM; Guise CP; Maroz A; Anderson RF; Patterson AV; Stachelek GC; Glazer PM; Matteucci MD; Hart CP
    Mol Cancer Ther; 2012 Mar; 11(3):740-51. PubMed ID: 22147748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy.
    Kishimoto S; Brender JR; Chandramouli GVR; Saida Y; Yamamoto K; Mitchell JB; Krishna MC
    Antioxid Redox Signal; 2021 Oct; 35(11):904-915. PubMed ID: 32787454
    [No Abstract]   [Full Text] [Related]  

  • 15. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy.
    Saggar JK; Tannock IF
    Int J Cancer; 2014 Jun; 134(11):2726-34. PubMed ID: 24338277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.
    Hong CR; Dickson BD; Jaiswal JK; Pruijn FB; Hunter FW; Hay MP; Hicks KO; Wilson WR
    Biochem Pharmacol; 2018 Oct; 156():265-280. PubMed ID: 30134191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo.
    Huang Y; Tian Y; Zhao Y; Xue C; Zhan J; Liu L; He X; Zhang L
    Cancer Commun (Lond); 2018 May; 38(1):15. PubMed ID: 29764490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer.
    Bailey KM; Cornnell HH; Ibrahim-Hashim A; Wojtkowiak JW; Hart CP; Zhang X; Leos R; Martinez GV; Baker AF; Gillies RJ
    PLoS One; 2014; 9(12):e113586. PubMed ID: 25532146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302.
    Lohse I; Rasowski J; Cao P; Pintilie M; Do T; Tsao MS; Hill RP; Hedley DW
    Oncotarget; 2016 Jun; 7(23):33571-80. PubMed ID: 27248663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect.
    Hong CR; Wilson WR; Hicks KO
    Neoplasia; 2019 Feb; 21(2):159-171. PubMed ID: 30591421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.